Apixaban in patients with atrial fibrillation - The New England Journal of Medicine - 2011

Brief Summary:

In patients with atrial fibrillation thought to be unsuitable candidates for anticoagulation with a vitamin K antagonist, apixaban signficantly reduced the risk of stroke and systemic embolism without increasing the risk of major bleeding or intracranial hemorrhage when compared to aspirin.

Reference: http://www.ncbi.nlm.nih.gov/pubmed/21309657